Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: B-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos. The supporters have no influence over the production of the content.

Welcome to The B-Cell Lymphoma Channel

VJHemOnc presents the latest in the world of B-cell lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and Burkitt lymphoma. The B-Cell Lymphoma Channel offers on-demand content including podcasts, roundtable discussions and exclusive video interviews with leading experts, so you can keep up with exciting updates in the field.

Explore The B-Cell Lymphoma Channel to learn about the latest advances in current chemotherapy and targeted agents, combinations, novel treatments including CAR T-cell therapies, as well as exciting novelties in diagnostic biomarkers.

Holding and bridging therapy selection in R/R aggressive B-cell lymphoma 2:56
Holding and bridging therapy selection in R/R aggressive B-cell lymphoma
Gloria Iacoboni • 4 Sep 2025
How the CNS-IPI score may be used to predict the risk of ICANS after CAR T-cell therapy 1:21
How the CNS-IPI score may be used to predict the risk of ICANS after CAR T-cell therapy
Gloria Iacoboni • 4 Sep 2025
Evolving role of CAR-T and bispecifics in B-cell lymphoma: from R/R to frontline 2:35
Evolving role of CAR-T and bispecifics in B-cell lymphoma: from R/R to frontline
Gloria Iacoboni • 4 Sep 2025
Short-term patient-reported adverse events & HRQoL by CAR-T product in aggressive B-cell lymphomas 1:12
Short-term patient-reported adverse events & HRQoL by CAR-T product in aggressive B-cell lymphomas
Fabio Efficace • 14 Jun 2025
The use of BOOM-BOOM radiation prior to liso-cel in aggressive B-cell non-Hodgkin lymphoma 3:36
The use of BOOM-BOOM radiation prior to liso-cel in aggressive B-cell non-Hodgkin lymphoma
Christopher D'Angelo • 13 Jun 2025
Safety and efficacy of pirtobrutinib in patients with covalent BTKi-intolerant B-cell malignancies 1:19
Safety and efficacy of pirtobrutinib in patients with covalent BTKi-intolerant B-cell malignancies
Nirav Niranjan Shah • 20 Jun 2025
The evolving role of autoSCT for B-cell lymphoma in the era of CAR-T & selecting patients for SCT 2:28
The evolving role of autoSCT for B-cell lymphoma in the era of CAR-T & selecting patients for SCT
Paolo Strati • 18 Jun 2025
Exploring the use of ctDNA for monitoring MRD in patients with PMBCL 2:28
Exploring the use of ctDNA for monitoring MRD in patients with PMBCL
Vincent Camus • 19 Jun 2025
The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies 0:54
The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
John Kuruvilla • 19 Jun 2025
Looking to the future of B-cell lymphoma treatment 1:02
Looking to the future of B-cell lymphoma treatment
Christian Buske • 14 Jun 2025
The value of newer-generation BTK inhibitors in R/R indolent B-cell lymphoma 2:16
The value of newer-generation BTK inhibitors in R/R indolent B-cell lymphoma
Paolo Strati • 18 Jun 2025
Acalabrutinib, lenalidomide, and rituximab in previously untreated indolent B-cell lymphoma 2:55
Acalabrutinib, lenalidomide, and rituximab in previously untreated indolent B-cell lymphoma
Paolo Strati • 18 Jun 2025
The LYSA guidelines for the diagnosis and management of primary mediastinal B-cell lymphoma 2:38
The LYSA guidelines for the diagnosis and management of primary mediastinal B-cell lymphoma
Vincent Camus • 18 Jun 2025
The real-world outcomes of tisa-cel in patients with aggressive B-cell lymphoma 1:34
The real-world outcomes of tisa-cel in patients with aggressive B-cell lymphoma
Daniel Landsburg • 18 Jun 2025
A first-in-human Phase I study of iPSC-derived CAR-NK cells in B-cell lymphoma 2:46
A first-in-human Phase I study of iPSC-derived CAR-NK cells in B-cell lymphoma
Paolo Strati • 18 Jun 2025
The feasibility of alloSCT as consolidation therapy in R/R B-cell lymphoma exposed to bispecifics 1:36
The feasibility of alloSCT as consolidation therapy in R/R B-cell lymphoma exposed to bispecifics
Alberto Mussetti • 31 Mar 2025

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals